SLC5A2 and chronic kidney disease: SGLT-2 inhibitors, originally used for improving glycemic control in T2D, have been consistently shown to reduce the risk of adverse cardiovascular events, worsening heart failure, and chronic kidney disease progression in both diabetic and non-diabetic patients [65].